Phase II doseselection, randomized double-blind trial of the ASI, BI 690517, alone and in combination with EMPA in people with CKD

Publication Title

60th ERA Congress 2023

Document Type

Presentation

Publication Date

6-2023

Keywords

washington; spokane; pmrc

Abstract

This study is investigating the efficacy and safety of three doses of BI 690517, alone and in combination with empagliflozin (EMPA), on top of an ACEi or ARB, for treatment of CKD with or without type 2 diabetes. This study will provide key data on the potential synergistic kidney-protective effects and safety of combination therapy with BI 690517 plus EMPA, as well as data on monotherapy, for CKD with or without type 2 diabetes. Findings will inform BI 690517 dose selection for further clinical trial development.

Clinical Institute

Kidney & Diabetes

Specialty/Research Institute

Nephrology

Specialty/Research Institute

Endocrinology

Comments

  • Tuttle, Katherine R., University of Washington, Seattle, Washington, United States
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Cronin, Lisa, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
  • Hauske, Sibylle Jenny, Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Hussain, Joanna, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • de Zeeuw, Dick, University Medical Center Groningen, Groningen, Netherlands
  • L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands

This document is currently not available here.


Share

COinS